%0 Journal Article
%K Adult
%K Humans
%K Prognosis
%K *Methotrexate/adverse effects
%K Retrospective Studies
%K *Drug-Related Side Effects and Adverse Reactions
%K Primary health care
%K United Kingdom/epidemiology
%B Bmj
%D 2023
%G eng
%M 37253479
%P e074678
%R 10.1136/bmj-2022-074678
%T Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK
%V 381
%2 PMC10227711 at www.icmje.org/disclosure-of-interest/ and declare: support from the National Institute for Health and Care Research. AA has received institutional research grants from AstraZeneca and Oxford Immunotech and personal fees from UpToDate (royalty), Springer (royalty), Cadilla Pharmaceuticals (lecture fees), NGM Bio (consulting), and Limbic (consulting), and personal fees from Inflazome (consulting) unrelated to the work. GP Aithal has received consulting fees from Clinipace, Amryth, GSK, DNDi, Pfizer, BenevolentAI Bio, Albireo Pharma, Abbott Products Operations, AstraZeneca, Merck, and PureTech paid to the University of Nottingham unrelated to the work. CPF has received consultancy or advisory board fees from Abbvie, GenMab, Incyte, Lily, Morphosys, Roche, Takeda, Ono, Kite/Gilead, BMS/Celgene, and BTG/Veriton and departmental research funding from BeiGene unrelated to the work.
%7 2023/05/31
%@ 0959-8138 (Print)
0959-8138